Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ventyx Biosciences

Request full access

A biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets

Encinitas, United StatesFounded 2018Biotech & Life Sciences

About Ventyx Biosciences

Ventyx Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm, directing its efforts toward the development of selective, small molecule oral therapies for a range of autoimmune diseases. The company, which was founded in 2018, is headquartered in San Diego, California. Its establishment was the result of the merger of three companies: Oppilan Pharma, Zomagen Biosciences, and Ventyx, all of which were portfolio companies of New Science Ventures. This strategic consolidation brought together a diversified pipeline of clinical and preclinical assets aimed at immunology.

The company's business model is centered on identifying and advancing promising drug candidates through the various stages of clinical development. Ventyx targets the immunology and inflammation markets, developing treatments for conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its revenue generation is prospective, contingent upon the successful commercialization of its product candidates or through strategic partnerships and licensing agreements with other pharmaceutical companies.

Ventyx's drug pipeline features several candidates. VTX958 is a tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of psoriasis, psoriatic arthritis, and Crohn's disease. Another key asset is VTX002, a sphingosine 1 phosphate receptor (S1P1R) modulator developed for patients with moderate-to-severe ulcerative colitis. The portfolio also includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor, targeting systemic and neuroinflammatory diseases. These molecules are designed to be taken orally, offering a potential convenience advantage over injectable biologics that currently dominate the market for many autoimmune disorders. In October 2021, Ventyx Biosciences successfully launched its initial public offering (IPO), raising approximately $174.3 million in gross proceeds to fund its research and development activities.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Ventyx Biosciences in the Encinitas ecosystem

Live from Dealroom

The Ventyx Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A14 investors entered at this stage

Series B and later8 investors entered at this stage

  • Redmile Group
  • EcoR1 Capital
  • CaaS Capital Management
  • Great Point Partners
  • Driehaus Capital Management
  • Walleye Capital
  • Woodline Partners
  • Sanofi
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$21M

16 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Ventyx Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.